Related Experiment Video

Updated: Jun 16, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

369

Key Points in Managing PLA2R-Associated Membranous Nephropathy

Raja Ramachandran1, Vivekanand Jha2,3,4, Bhadran Bose5

  • 1Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Kidney International Reports
|August 19, 2024
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

442
Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis
08:55

Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis

Published on: August 7, 2018

10.8K

Related Experiment Videos

Last Updated: Jun 16, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

369
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

442
Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis
08:55

Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis

Published on: August 7, 2018

10.8K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

79
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
79

Articles linked to this work by shared authors, journal, and citation graph.

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.

JAMA·2026

Complementary and alternative medicine-associated membranous nephropathy: a systematic review.

Journal of nephrology·2026

Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study.

Nephrology (Carlton, Vic.)·2026

Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial.

American journal of nephrology·2026

Corrigendum to "Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy" [<i>Kidney International Reports</i> Volume 10, Issue 11, November 2025, Pages 3785-3795].

Kidney international reports·2026

Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy.

Kidney international reports·2025

Anti-CD20 Therapies and Antinephrin Autoantibodies in IgA Nephropathy With Minimal Change Disease.

Kidney international reports·2026

Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.

Kidney international reports·2026

IgG4-Related Kidney Disease and IgG4-Related Retroperitoneal Fibrosis: An Update on Diagnosis and Treatment.

Kidney international reports·2026

Association of FHR5 With Disease Severity in ANCA-Associated Vasculitis.

Kidney international reports·2026

Characterization of Patient-Reported Loin Pain in IgAN.

Kidney international reports·2026

Systematic Review of Kidney Involvement in Antisynthetase Syndrome.

Kidney international reports·2026

Notoginsenoside R1 Alleviates Acetaminophen-Induced Liver Injury via MAPK/mTOR-Mediated Autophagy.

The American journal of Chinese medicine·2026

Tryptophan-Mediated Sodium Dodecyl Sulfate Binding to Proteins.

The protein journal·2026

Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein-protein interaction modulators.

Acta pharmacologica Sinica·2026

Promiscuity of Cytochrome P450 Enzymes: Discovery Strategies, Mechanistic Insights, and Applications in Terpenoid Biosynthesis.

Journal of agricultural and food chemistry·2026

Topical Sirolimus Therapy for Agminated Pyogenic Granulomas: A Two-Case Report.

Pediatric dermatology·2026

HELM-BERT: Topology-Aware Representations for Chemically Modified Peptides.

Journal of chemical information and modeling·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us